Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi; Giuseppe Procopio; Diana Giannarelli; Roberto Sabbatini; Alessandra Bearz; Sebastiano Buti; Umberto Basso; Manfred Mitterer; Cinzia Ortega; Paolo Bidoli; Francesco Ferraù; Lucio Crinò; Antonio Frassoldati; Paolo Marchetti; Enrico Mini; Alessandro Scoppola; Claudio Verusio; Giuseppe Fornarini; Giacomo Cartenì; Claudia Caserta; Cora N Sternberg

doi:10.1158/1078-0432.CCR-18-3661

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli, Roberto Sabbatini, Alessandra Bearz, Sebastiano Buti, Umberto Basso, Manfred Mitterer, Cinzia Ortega, Paolo Bidoli, Francesco Ferraù, Lucio Crinò, Antonio Frassoldati, Paolo Marchetti, Enrico Mini, Alessandro Scoppola, Claudio Verusio, Giuseppe Fornarini, Giacomo Cartenì, Claudia CasertaCora N Sternberg

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. EXPERIMENTAL DESIGN: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

Original language	English
Pages (from-to)	3839-3846
Number of pages	8
Journal	Clin. Cancer Res.
Volume	25
Issue number	13
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-3661
Publication status	Published - Jul 1 2019

Access to Document

10.1158/1078-0432.CCR-18-3661

https://www.ncbi.nlm.nih.gov/pubmed/30967420

Cite this

De Giorgi, U., Procopio, G., Giannarelli, D., Sabbatini, R., Bearz, A., Buti, S., Basso, U., Mitterer, M., Ortega, C., Bidoli, P., Ferraù, F., Crinò, L., Frassoldati, A., Marchetti, P., Mini, E., Scoppola, A., Verusio, C., Fornarini, G., Cartenì, G., ... Sternberg, C. N. (2019). Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. Clin. Cancer Res., 25(13), 3839-3846. https://doi.org/10.1158/1078-0432.CCR-18-3661

De Giorgi, U , Procopio, G , Giannarelli, D, Sabbatini, R, Bearz, A, Buti, S, Basso, U, Mitterer, M, Ortega, C, Bidoli, P, Ferraù, F, Crinò, L, Frassoldati, A, Marchetti, P, Mini, E, Scoppola, A, Verusio, C, Fornarini, G, Cartenì, G, Caserta, C & Sternberg, CN 2019, 'Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab', Clin. Cancer Res., vol. 25, no. 13, pp. 3839-3846. https://doi.org/10.1158/1078-0432.CCR-18-3661

@article{470d6d5eb4b54230867743beee894c2e,

title = "Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab",

abstract = "PURPOSE: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. EXPERIMENTAL DESIGN: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR) ",

author = "{De Giorgi}, Ugo and Giuseppe Procopio and Diana Giannarelli and Roberto Sabbatini and Alessandra Bearz and Sebastiano Buti and Umberto Basso and Manfred Mitterer and Cinzia Ortega and Paolo Bidoli and Francesco Ferra{\`u} and Lucio Crin{\`o} and Antonio Frassoldati and Paolo Marchetti and Enrico Mini and Alessandro Scoppola and Claudio Verusio and Giuseppe Fornarini and Giacomo Carten{\`i} and Claudia Caserta and Sternberg, {Cora N}",

year = "2019",

month = jul,

day = "1",

doi = "10.1158/1078-0432.CCR-18-3661",

language = "English",

volume = "25",

pages = "3839--3846",

journal = "Clin. Cancer Res.",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

AU - De Giorgi, Ugo

AU - Procopio, Giuseppe

AU - Giannarelli, Diana

AU - Sabbatini, Roberto

AU - Bearz, Alessandra

AU - Buti, Sebastiano

AU - Basso, Umberto

AU - Mitterer, Manfred

AU - Ortega, Cinzia

AU - Bidoli, Paolo

AU - Ferraù, Francesco

AU - Crinò, Lucio

AU - Frassoldati, Antonio

AU - Marchetti, Paolo

AU - Mini, Enrico

AU - Scoppola, Alessandro

AU - Verusio, Claudio

AU - Fornarini, Giuseppe

AU - Cartenì, Giacomo

AU - Caserta, Claudia

AU - Sternberg, Cora N

PY - 2019/7/1

Y1 - 2019/7/1

N2 - PURPOSE: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. EXPERIMENTAL DESIGN: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

AB - PURPOSE: Inflammation indexes and body mass index (BMI) are easily evaluated, predict survival, and are potentially modifiable. We evaluated the potential association of inflammatory indexes and BMI with the clinical outcome of patients with renal cell carcinoma (RCC) undergoing immune checkpoint inhibitor therapy. EXPERIMENTAL DESIGN: A prospective cohort of patients with metastatic RCC treated with nivolumab enrolled in the Italian Expanded Access Program from July 2015 through April 2016 was examined. Reference measures of inflammation were identified for neutrophil-to-lymphocyte ratio (NLR)

U2 - 10.1158/1078-0432.CCR-18-3661

DO - 10.1158/1078-0432.CCR-18-3661

M3 - Article

SN - 1078-0432

VL - 25

SP - 3839

EP - 3846

JO - Clin. Cancer Res.

JF - Clin. Cancer Res.

IS - 13

ER -

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Abstract

Access to Document

Fingerprint

Cite this